Clinical Trial Detail

NCT ID NCT02794883
Title Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications

malignant glioma

Therapies

Tremelimumab

Durvalumab + Tremelimumab

Durvalumab

Age Groups: adult

No variant requirements are available.